Nicole Hassoun and Priya Bhimani outline the benefits of the recently developed Global Health Impact index.
For much of 2014, the Ebola outbreak in Sub-Saharan Africa dominated headlines as the virus spread and eventually made its way to the United States and Europe. Unfortunately, while the world focused on graphic images of people dying from Ebola on the street, little attention was paid to other infectious diseases that continue to plague much of the developing world.
As media coverage of the Ebola outbreak slowly started to decline, however, news of a new strain of drug-resistant malaria started to catch the public’s attention. Drug-resistance is a silent but serious threat to public health. And, if drug-resistant malaria were to spread from its current location in Myanmar to the nearby nations of India and China, it could easily become the world’s next big global health emergency.
More generally, every year millions of people die from malaria, tuberculosis, and HIV/AIDs – aptly named neglected diseases. This fact invites the following questions: What efforts to combat these neglected diseases are working? Where is help still needed? And, what initiatives are actually making a difference?
A new Global Health Impact index, supported by a collaboration of university-based researchers and civil society organizations around the world, helps provide answers to these questions. The index evaluates the global health impact of particular drugs. This information can be used to increase awareness about particular diseases, and create national and international demand for drugs to treat these diseases.
A drug’s global health impact is determined by compiling information about: (1) the need for the drug; (2) access to the drug; and (3) effectiveness of the drug.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.